Sonoma Pharmaceuticals, Inc. 8-K

What Happened

• Sonoma Pharmaceuticals, Inc. (SNOA) announced an underwriting agreement with Dawson James Securities, Inc. and a public offering of 2,962,962 units at $1.35 per unit (each unit = one share of common stock or, if needed to avoid >4.99% ownership, a pre‑funded warrant, plus one common warrant). The agreement was dated April 24, 2026; the company’s registration statement (S‑1) was declared effective April 23, 2026, and the final prospectus was filed April 27, 2026. The offering closed April 27–28, 2026, with the 45‑day over‑allotment option fully exercised.

Key Details

• Offering size and structure: 2,962,962 units at $1.35 per unit; over‑allotment exercised for an additional 444,444 shares/warrants.
• Securities issued at closing: 1,650,716 common shares; 1,312,247 pre‑funded warrants (to purchase common shares); and 3,407,404 common warrants exercisable at $1.35 per share, expiring five years from issuance.
• Proceeds and fees: Estimated net proceeds ≈ $3.5 million after underwriting discount and expenses. Underwriter fee = 7.5% of gross proceeds; non‑accountable expense allowance = 1% of proceeds; up to $75,000 of offering expenses reimbursed. Dawson James received a warrant to purchase up to 5% of securities sold (exercisable 6 months after closing at 110% of the public offering price).
• Other terms: 90‑day lock‑up on company, officers and directors (subject to limited exceptions). Computershare entities appointed as warrant agents for the issued warrants and pre‑funded warrants.

Why It Matters

• This 8‑K signals a capital raise that provides Sonoma with roughly $3.5M in immediate net proceeds to fund operations or other corporate needs, and potential additional cash if the issued warrants are exercised. The deal dilutes existing shareholders (new shares and warrants issued) and includes typical underwriting costs and a short insider lock‑up period. Investors should note the number of warrants outstanding and their five‑year term at $1.35, since exercises would bring additional capital and further dilution. The filing also includes customary risk and forward‑looking statement language.